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Abstract
Background: It has been hypothesized that heteromers of adenosine A2A receptors (A2AR) and cannabinoid CB1
receptors (CB1R) localized in glutamatergic nerve terminals mediate the integration of adenosine and endocannabinoid
signaling involved in the modulation of striatal excitatory neurotransmission. Previous studies have demonstrated the
existence of A2AR-CB1R heteromers in artificial cell systems. A dependence of A2AR signaling for the Gi protein-mediated
CB1R signaling was described as one of its main biochemical characteristics. However, recent studies have questioned the
localization of functionally significant A2AR-CB1R heteromers in striatal glutamatergic terminals.
Results: Using a peptide-interfering approach combined with biophysical and biochemical techniques in mammalian
transfected cells and computational modeling, we could establish a tetrameric quaternary structure of the A2AR-CB1R
heterotetramer. This quaternary structure was different to the also tetrameric structure of heteromers of A2AR with
adenosine A1 receptors or dopamine D2 receptors, with different heteromeric or homomeric interfaces. The specific
quaternary structure of the A2A-CB1R, which depended on intermolecular interactions involving the long C-terminus
of the A2AR, determined a significant A2AR and Gs protein-mediated constitutive activation of adenylyl cyclase. Using
heteromer-interfering peptides in experiments with striatal glutamatergic terminals, we could then demonstrate the
presence of functionally significant A2AR-CB1R heteromers with the same biochemical characteristics of those studied
in mammalian transfected cells. First, either an A2AR agonist or an A2AR antagonist allosterically counteracted Gi-
mediated CB1R agonist-induced inhibition of depolarization-induced glutamate release. Second, co-application of both
an A2AR agonist and an antagonist cancelled each other effects. Finally, a CB1R agonist inhibited glutamate release
dependent on a constitutive activation of A2AR by a canonical Gs-Gi antagonistic interaction at the adenylyl cyclase
level.
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Conclusions: We demonstrate that the well-established cannabinoid-induced inhibition of striatal glutamate release
can mostly be explained by a CB1R-mediated counteraction of the A2AR-mediated constitutive activation of adenylyl
cyclase in the A2AR-CB1R heteromer.
Keywords: Adenosine A2A receptor, Cannabinoid CB1 receptor, GPCR heteromers, Adenylyl cyclase, Glutamate transmission,
Striatum,
Background
Adenosine and endocannabinoids, such as anandamide
and 2-arachidonylglycerol (2-AG), are very ubiquitous
non-classical neurotransmitters that modulate the trans-
mission ensured by other more classical neurotransmit-
ters. In the striatum, the modulatory role of adenosine
and endocannabinoids converge in excitatory synapses,
where their signaling is integrated by G protein-coupled
receptors (GPCRs) localized in glutamatergic nerve termi-
nals [1]. Adenosine is produced from the conversion of
ATP (by ectonucleotidases) that is co-released with
glutamate from the nerve terminals and from astrocytes
[1, 2]. Adenosine can then bind and activate adenosine re-
ceptors of the A1 or A2A subtype (A1R or A2AR, respect-
ively) localized presynaptically, promoting inhibition or
facilitation of glutamate release, respectively [1–3]. On the
other hand, endocannabinoids are produced “on demand”
from endocannabinoid precursors by the action of en-
zymes localized in the postsynaptic plasma membrane [4].
One of the best studied functions of endocannabinoids is
“retrograde signaling” with stimulation of presynaptic can-
nabinoid CB1 receptors (CB1R) and the consequent inhib-
ition of neurotransmitter release [4].
We have previously hypothesized that adenosine and
endocannabinoids exert a fine-tune modulation of striatal
glutamate release from striatal glutamatergic terminals, by
which low adenosine plus high endocannabinoid tone
would produce the weakest, while high adenosine plus
low endocannabinoid tone would produce the strongest
glutamate release [1]. We also hypothesized that this fine-
tune modulation depends, not only on the adenosine and
endocannabinoid tone, but on the ability of specific sub-
types of adenosine and cannabinoid receptors to form het-
eromers, mainly A1R-A2AR and A2AR-CB1R heteromers,
and on their unique biochemical properties (reviewed in
[1]). A1R-A2AR heteromers have been characterized both
functionally and structurally, but some inconsistencies re-
main about the functional properties of A2AR-CB1R het-
eromers and even about their existence in striatal
glutamatergic terminals (see below).
The A1R-A2AR heteromer acts as a concentration-
dependent switch that mediates the adenosine control of
striatal glutamatergic transmission [3]. Since adenosine
binds with higher affinity to A1R than to A2AR [5], low
concentrations of adenosine inhibit glutamate release by
activating the Gi-coupled A1R [3]. On the other hand,
high concentrations of adenosine produce the opposite
effect, by activating the Gs-coupled A2AR, which pro-
motes glutamate release by activating adenylyl cyclase
(AC)-PKA signaling and allosterically counteracting A1R
signaling within the A1R-A2AR heteromer [3, 6]. The
quaternary structure of the A1R-A2AR heteromer has
been recently proposed and shown to be heterotetra-
meric, constituted by homodimers of A1R and A2AR
coupled to their cognate G proteins [6]. This is similar
to the also recently described quaternary structure of the
A2AR-dopamine D2 receptor (D2R) heteromer [7],
which is localized postsynaptically in the striatum [8].
It has been recently demonstrated that the A2AR-D2R
heteromer forms part of functional complexes that in-
clude A2AR-D2R heterotetramers, constituted by A2AR
and D2R homodimers with their respective cognate Gs
and Gi proteins, and AC subtype AC5 [7]. The quater-
nary structure of these complexes is stabilized by specific
interactions between transmembrane domains (TMs) of
the receptors, which determine the homomeric and het-
eromeric interfaces in the A2AR-D2R heterotetramer, as
well as between TMs of the receptors and TMs of AC5
[7]. In addition, interactions between intracellular do-
mains play a significant role in the stabilization of the
complex, namely a strong electrostatic interaction be-
tween the C-terminal domain of the A2AR (A2AR-CT)
and the intracellular end of TM 5 of the D2R [9–12]
and between the N-terminal domain (NT) of AC5 and
βγ-subunits of the G proteins [13]. The predicted qua-
ternary structure of the A2AR-D2R heterotetramer in
complex with AC5 provided the frame for the canonical
Gs-Gi antagonistic interaction at the AC level [7]. This
canonical interaction implies the ability of an activated
Gi-coupled receptor to inhibit AC activation by a Gs-
coupled receptor [14] and requires the simultaneous
respective interaction of the Ras-GTPase domain of the
α-subunits of the Gs and Gi proteins with the C2 and
C1 catalytic domains of AC [15].
Importantly, the heteromeric and homomeric interfaces
of the A1R-A2AR heterotetramer were found to be differ-
ent from those of the A2AR-D2R heterotetramer [6, 7].
The consequent different conformation of the A1R-A2AR
heterotetramer was associated with its inability to sustain
a canonical Gs-Gi antagonistic interaction at the AC level
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[6]. Particularly striking was the involvement of A2AR-
CT, because its deletion enabled the canonical Gs-Gi an-
tagonistic interaction by the A1R-A2AR heteromer. On
the other hand, contrary to the A2AR-D2R heterotetra-
mer, A2AR-CT deletion did not disrupt A1R-A2AR het-
eromerization, indicating its lack of involvement on the
stabilization of the quaternary structure of the A1R-A2AR
heterotetramer [6]. These results also indicated that the
ability of A1R in the A1R-A2AR heteromer to mediate in-
hibition of glutamate release in the striatal glutamatergic
terminals was not dependent on the canonical Gs-Gi an-
tagonistic interaction at the AC level and, therefore, on
the inhibition of A2AR-mediated AC-PKA signaling. In-
stead, it would be most probably dependent on the clas-
sical inhibitory effect of βγ-subunits on presynaptic
calcium channels [16, 17].
The ability of A2AR and CB1R to heteromerize was
first suggested from results obtained in artificial cell sys-
tems using biophysical techniques [18]. In the same
study, signaling experiments performed in a neuroblast-
oma cell line indicated the existence of the conventional
G protein coupling for both receptors and a dependence
on A2AR signaling for the expression of the Gi-
mediated inhibition of AC activity by CB1R agonists
[18]. As expected from the canonical interaction at the
AC level, a CB1R agonist could counteract an A2AR
agonist-induced AC activation. But, A2AR blockade also
counteracted the ability of a CB1R agonist to inhibit
forskolin-induced AC activation [18]. It was then sug-
gested that activation of A2AR in the A2AR-CB1R het-
eromer allows the effective coupling of CB1R to Gi
proteins and, consequently, that CB1R signaling is en-
tirely dependent on A2AR signaling [18]. Strong evi-
dence for physical interactions between A2AR and CB1R
in striatal glutamatergic terminals was afterwards
reported, including a robust co-localization and co-
immunoprecipitation [19]. In the same study, an A2AR
agonist significantly decreased the potency of a CB1R
agonist to inhibit striatal glutamate release and pre-
synaptic corticostriatal glutamatergic transmission [19].
More in line with the expected dependence on A2AR acti-
vation within the A2AR-CB1R heteromer, some studies
also found evidence for counteraction of CB1R-mediated
corticostriatal transmission by A2AR antagonists [20, 21].
Although apparently incompatible with the involve-
ment of a single population of A2AR, forming hetero-
mers with CB1R, similar effects of A2AR agonists and
antagonists have also been obtained with the A2AR-D2R
heteromer and found to depend on allosteric interac-
tions that depend on its tetrameric structure. When ei-
ther an A2AR agonist or an A2AR antagonist binds to
the orthosteric sites of the A2AR homodimer in the
A2AR-D2R heterotetramer, they both produce an allo-
steric decrease in the affinity and efficacy of D2R ligands
[12]. On the other hand, when an agonist and an antag-
onist bind simultaneously to the two orthosteric sites of
the A2AR homodimer, they counteract each other’s ef-
fects [12]. At the biochemical level, a negative allosteric
interaction between orthosteric A2AR agonists and an-
tagonists in an A2AR homodimer could be demon-
strated in dissociation kinetic binding experiments of a
radiolabeled A2AR antagonist versus A2AR agonists and
antagonists, including the non-selective antagonist caf-
feine [12]. At the behavioral level, these homomeric allo-
steric interactions could better explain the psychomotor
stimulant effects of caffeine and selective A2AR antago-
nists than the classically assumed competitive antagon-
ism between A2AR antagonists and endogenous
adenosine for the same orthosteric site [22, 23]. Thus,
the allosteric homomeric interactions between A2AR ag-
onists and antagonists predicted a counterintuitive coun-
teraction of a high locomotor depressant dose of an
A2AR antagonist in the rat with an also locomotor de-
pressant dose of an A2AR agonist in the rat [22].
There is therefore a significant amount of evidence
that supports the existence of functional A2AR-CB1R
heteromers in the striatal glutamatergic terminals with
similar structural and biochemical characteristics to
those of the A2AR-D2R heteromers and that they con-
stitute a main population of CB1R that play an essential
role in striatal synaptic transmission and plasticity [24–
28]. However, in a recent study, A2AR-CB1R complexes
were identified by the proximity ligation assay in the
mouse striatum and suggested to represent A2AR-CB1R
heteromers localized postsynaptically in GABAergic
striatopallidal neurons, but not in corticostriatal termi-
nals. This conclusion was based on results obtained in
mice with differential genetic blockade of CB1R in fore-
brain GABAergic neurons versus dorsal telencephalic
glutamatergic neurons [29]. In addition, parallel experi-
ments in conditionally immortalized striatal neuroblasts
suggested that A2AR-CB1R heteromers signal by Gq
protein coupling, but not through Gs and Gi proteins
[29]. In view of these apparently controversial results,
the goals of the present study were, first, to establish the
quaternary structure and biochemical properties of the
A2AR-CB1R heteromer and to compare them with those
of the A1R-A2AR and A2AR-D2R heterotetramers. Sec-
ond, we aimed at establishing the localization, biochem-
ical properties, and functional significance of the A2AR-
CB1R heteromers in the striatal glutamatergic terminals.
Results
A2AR and CB1R in the A2AR-CB1R heteromer couple to
their respective cognate Gs and Gi proteins in HEK-293T
cells
The complemented donor-acceptor resonance energy
transfer (CODA-RET) assay was first used to analyze the
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preferred functional G protein coupling of A2AR and
CB1R in the A2AR-CB1R heteromer, in transiently
transfected HEK-293T cells. In this assay, two comple-
mentary halves of the bioluminescent protein Renilla lu-
ciferase (Rluc8 variant; nRluc and cRluc) are separately
fused to two different GPCR units (protomers) putatively
able to oligomerize, and a fluorescent protein, the mVe-
nus variant of the yellow fluorescence protein (YFP), is
fused to a Gα protein subunit. Ligand-induced changes
in CODA-RET measurements imply, first, a successful
complementation of Rluc and, therefore, oligomerization
of the corresponding protomers. Second, although
CODA-RET does not provide an estimate of the degree
of oligomerization (affinity or stoichiometry), it repre-
sents the reading of a specific G protein activation
through the GPCR heteromer [30–32]. A2AR was fused
to cRluc, and CB1R was fused to nRluc and co-
transfected with either Gαs, Gαi1 or Gαq fused to YFP.
Concentration-response curves of ligand-induced
changes in BRET were then determined in the presence
of different concentrations of the non-selective adeno-
sine receptor agonist NECA or the selective CB1R agon-
ist CP55940. A concentration-response curve with
NECA could only be obtained when the cells were trans-
fected with Gαs-YFP (EC50 values, in mean ± S.E.M:
0.35 ± 0.08 μM; n = 5 with triplicates), but not with
Gαi1-YFP or Gαq-YFP (Additional file 1: Figure S1a;
Additional file 2: Data values 1). On the other hand, a
concentration-response with CP55940 could only be ob-
tained when the cells were transfected with Gαi-YFP
(EC50 values, in mean ± S.E.M: 1.05 ± 0.39 μM; n = 5
with triplicates), but not with Gαs-YFP or Gαq-YFP
(Additional file 1: Figure S1b; Additional file 2: Data
values 1). A positive control of Gq coupling by a GPCR
heteromer was obtained with the previously reported
serotonin 5-HT2A receptor (5-HT2AR)-D2R heteromer
[33, 34]. A concentration-response curve was obtained
with serotonin, but not dopamine, when the cells were
transfected with 5-HT2AR fused to cRluc, D2R fused to
nRluc and Gαq-YFP (EC50 values, in mean ± S.E.M: 0.21
± 0.05 μM; n = 5 with triplicates) (Additional file 1:
Figure S1c; Additional file 2: Data values 1). These re-
sults indicate that within the A2AR-CB1R heteromer,
A2AR and CB1R preferentially couple to their respective
cognate Gs and Gi proteins. Nevertheless, the results do
not discard the possible coupling to Gq by A2AR and
CB1R in the A2AR-CB1R heteromer in another cellular
environment, such as in the conditionally immortalized
striatal neuroblasts and in the striatum, in the GABAer-
gic striatopallidal neurons or astrocytes [29].
Remarkably, NECA (10 μM) produced a shift to the right
in the concentration-response curve of CP55940 (Fig. 1a),
with a significant increase in EC50 values (Fig. 1b) and no
significant difference in the Emax values (Fig. 1c). These
results represent a readout of a negative allosteric inter-
action between two orthosteric agonists within the A2AR-
CB1R heteromer, by which an A2AR agonist decreases the
potency of a CB1R agonist-mediated Gi protein activation.
If the A2AR-CB1R heteromer would exhibit a tetrameric
structure similar to the A2AR-D2R heterotetramer, we
could expect the same allosteric interaction with A2AR ag-
onists and antagonists and their counteracting effect when
simultaneously applied (see “Background” and ref. [12]). In
fact, both NECA and caffeine produced a concentration-
dependent decrease of the change in BRET ratio values in-
duced by an EC50 concentration of CP55940 (2 μM; Fig.
1d, e). In addition, effective concentrations of NECA (10
μM; Fig. 1d) and caffeine (3 mM; Fig. 1e) became ineffective
when co-applied (Fig. 1e). These results therefore recapitu-
late allosteric interactions within the A2AR-D2R heterote-
tramer and, therefore, suggest an also tetrameric structure
of the A2AR-CB1R heteromer.
We also analyzed the possible opposite allosteric inter-
action by which a CB1R agonist could modify the potency
of an A2AR agonist-mediated Gs protein activation (cells
transfected with Gαs-YFP). CP55940 did not produce a sig-
nificant shift in the concentration-response curve of NECA.
EC50 values of the concentration-response curves of NECA
in the absence and presence of CP55940 (10 μM) were, in
mean ± S.E.M, 0.52 ± 0.23 μM and 0.57 ± 0.13 μM, respect-
ively (paired t test: p > 0.05; n = 5 with triplicates); Emax
values in the absence and presence of CP55940 (10 μM)
were, in mean ± S.E.M, 0.009 ± 0001 and 0.009 ± 0.001
BRET ratio units (BRU), respectively (paired t test: p > 0.05;
n = 5 with triplicates) (Additional file 1: Figure S2; Add-
itional file 2: Data values 2). These results indicate the exist-
ence of a unidirectional allosteric modulation between
orthosteric ligands in the A2AR-CB1R heteromer.
The A2AR-CB1R heteromer has a different quaternary
structure compared to the A2AR-D2R and the A1R-A2AR
heterotetramers
The possible heterotetrameric structure of the A2AR-
CB1R heteromers was further evaluated in HEK-293T
transfected cells by a BRET experiment based on the
double complementation of both BRET bioluminescent
and fluorescent proteins [12, 31], with complementary
halves of Rluc and YFP separately fused to different pro-
tomers of A2AR and CB1R. As shown in Additional file
1: Figure S3, significantly higher BRET values could be
obtained with co-transfection of A2AR-cRluc, A2AR-
nRluc, CB1R-cYFP, and CB1R-nYFP, as compared
with controls, where the A2AR or CB1R constructs
were substituted by dopamine D1 receptor (D1R) con-
structs, D1R-cRluc and D1R-nRluc or D1R-cYFP and
D1R-nYFP.
Bimolecular fluorescence complementation (BiFC) ex-
periments with synthetic interfering peptides were then
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performed to elucidate the homomeric and heteromeric
interfaces of the heterotetramer, which is the same strat-
egy that was used to reveal the precise quaternary struc-
ture of the A1R-A2AR and A2AR-D2R heterotetramers
[6, 7]. While BiFC complex formation under in vitro
conditions (purified complementary fluorescent pro-
teins) has been considered to be essentially irreversible
[35], several studies, including our own on GPCR
heteromers, indicate that under in vivo conditions (live
cell preparations) BiFC complex formation can be re-
versible [6, 7, 31, 36–38]. Complementary halves of YFP
were separately fused to A2AR (A2AR-cYFP) and CB1R
(CB1R-nYFP) or two different molecules of A2AR
(A2AR-nYFP and A2AR-cYFP) or CB1R (CB1R-nYFP
and CB1R-cYFP), in the absence and presence of syn-
thetic peptides with the amino acid sequence of all
Fig. 1 Modulation by A2AR ligands on CB1R-mediated G protein activation in the A2AR-CB1R heteromer. a–e CODA-RET experiments, where two
complementary halves of Rluc (cRluc and nRluc) are respectively fused to the A2AR and CB1R and YFP is fused to the α-subunit of Gi. HEK-293T
cells were transiently transfected with cDNAs of A2AR-cRluc (3.33 μg), CB1R-nRluc (1.67 μg), Gαi1-YFP (5 μg), and non-fused β1 and γ2 subunits
(4.5 μg and 5 μg, respectively). a Concentration-response curves of the effect of the selective CB1R agonist CP55940 on the ligand-induced BRET
changes, which are determined by changes in the interaction of the A2AR-CB1R heteromer with Gi, in the presence (blue plot) and absence (red
plot) of the non-selective adenosine agonist NECA (10 μM). Data are means ± S.E.M. of triplicate BRET ratio values of a representative experiment.
b, c EC50 and Emax values of 12 independent experiments performed in triplicate, expressed as means ± S.E.M.; the EC50 and Emax values were
obtained by non-linear regression fitting to a sigmoidal concentration-response curve and analyzed statistically with a paired t-test (*: p < 0.05,
compared with the absence of NECA). d, e Modification by NECA (1 and 10 μM), caffeine (CAFF, 1 and 3 mM) and NECA (10 μM) plus caffeine
(3 mM) on the effect of an EC50 concentration of CP55940 (2 μM); values are means ± S.E.M. (n = 10–11 with triplicates) of the percentage of the
effect of CPP55940 alone and analyzed statistically with repeated measures ANOVA, followed by Dunnett’s multiple comparison test (**: p < 0.01,
compared with CPP55940 alone)
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possible TMs of both receptors fused to the cell-
penetrating HIV transactivator of transcription (TAT)
sequence (TMs are abbreviated TM 1, TM 2,…; TM
peptides are abbreviated TM1, TM2,…). We could first
demonstrate the selective interference of BiFC of A2AR-
cYFP and CB1R-nYFP with TM5 and TM6 of both
A2AR and CB1R (Fig. 2a, b). These results point to the
involvement of TM 5/6 in the A2AR-CB1R heteromer
interface. Notably, the previously studied heteromer
interface of A1R-A2AR was also TM 5/6 [6], whereas
Fig. 2 Heteromeric and homomeric interfaces in the A2AR-CB1R heterotetramer. a–f BiFC experiments with synthetic peptides with the amino
acid sequence of all TMs of A2AR and CB1R. HEK-293T cells were transiently transfected with a, b cDNAs of A2AR and CB1R separately fused to
complementary halves of YFP (A2AR-cYFP and CB1-nYFP; 6 μg in both cases); c, e cDNAs of two different molecules of A2AR separately fused to
complementary halves of YFP (A2AR-cYFP and A2AR-nYFP; 3 μg in both cases) without (c) or with (e) co-transfection with cDNA of non-fused
CB1R (1 μg); d, f cDNAs of two different molecules of CB1R separately fused to complementary halves of YFP (CB1R-cYFP and CB1R-nYFP; 3 μg in
both cases) without (d) or with (f) co-transfection with cDNA of non-fused A2AR (1 μg). Cells were treated for 4 h with medium (control) or 4 μM
of indicated TM peptides (numbered 1–7). Values are means ± S.E.M. (n = 6 with triplicates in all the experiments) of the percentage of the
fluorescence in the control group and analyzed statistically with repeated measures ANOVA, followed by Dunnett’s multiple comparison test
(***: p < 0.001, compared with control)
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the heteromer interface of A2AR-D2R was found to be
TM 4/5 [7]. BiFC of A2AR-nYFP and A2AR-cYFP (in
the absence of CB1R) was only significantly reduced by
TM6 (Fig. 2c), as previously reported [7], and BiFC of
CB1R-nYFP and CB1R-cYFP (in the absence of A2AR)
was only reduced by TM4 (Fig. 2d). These results indi-
cate that TM 6 forms the A2AR interface and TM 4
forms the CB1R interface for homodimerization, when
each receptor is expressed alone. Significantly, the inter-
face for both CB1R-CB1R and A2AR-A2AR homodimers
changed in the presence of the other non-fused molecu-
larly different receptor (Fig. 2e, f). Thus, TM4 and TM6
of A2AR reduced BiFC of A2AR-cYFP and A2AR-nYFP
in the presence of non-fused CB1R (Fig. 2e) and TM4
and TM6 of CB1R reduced BiFC of CB1R-cYFP and
CB1R-nYFP in the presence of non-fused A2AR (Fig.
2f). The results in Fig. 2 are expressed as means ±
S.E.M. of the percentage of the fluorescence in the con-
trol group, where control values (without interfering
peptides) were always between 12,000 and 15,000 rela-
tive fluorescence units (RFU; value that depends on the
gain setting in the measurement equipment). Non-
transformed data show no significant change in fluores-
cence units upon co-transfection with a non-fused
receptor.
These results therefore demonstrate a change in a
GPCR homodimeric interface imposed by an additional
molecular interaction with another GPCR. Clearly, the
observed TM 4/6 interface for CB1R-CB1R and A2AR-
A2AR homodimerization in the A2AR-CB1R heterote-
tramer differs from the TM 4/5 interface for A1R-A1R
and A2AR-A2AR homodimerization in the A1R-A2AR
heterotetramer [6] and from the TM 6 interface for
A2AR-A2AR and D2R-D2R homodimerization in the
D2R-A2AR heterotetramer [7] (Fig. 3a). The almost
complete reduction of fluorescence to background fluor-
escence levels induced by the TM6 peptide of A2AR in
BiFC experiments with A2AR-nYFP and A2AR-cYFP in-
dicate that, without the presence of A1R or CB1R,
homodimerization with a TM 6 interface is the preferred
oligomerization state of the A2AR, while higher-order
A2AR oligomerization (homotrimers, heterotrimers) is
clearly unlikely. Even though concomitant homomeriza-
tion of A2AR by TM 6 or TM 4/5 interfaces is theoretic-
ally possible, our present and previous results indicate
that the latter interface is conditional upon heteromeri-
zation with A1R.
We next constructed, using computational tools (see
“Methods”), a structural model of the A2AR-CB1R het-
erotetramer using the information of the TM interfaces,
for homo- (TM 4/6) and hetero- (TM 5/6) dimerization,
derived from the BiFC experiments in the absence and
presence of the TAT-fused peptides. The symmetrical
TM 5/6 interface for heteromerization was modeled as
in the crystal structure of the μ-opioid receptor [39].
The modeling of a symmetrical TM 4/6 interface for
homomerization is not straightforward as it is not steric-
ally feasible that these two helices in one protomer sim-
ultaneously interact with the same helices in the other
protomer. To fit with the experimental data, in each ho-
modimer, TM 4 of the internal protomer engaged in
heteromerization should interact with TM 6 of the ex-
ternal protomer (an asymmetrical interface; Fig. 3a). In
fact, crystal structures and molecular dynamics (MD)
simulations have already provided evidence for the pos-
sibility that GPCRs show several possible symmetrical
and asymmetrical homomeric TM interfaces [40, 41].
What the present results indicate is that the preferred
homomeric interfaces can be determined by their het-
eromeric partner in a GPCR heterotetramer.
In our model of the A2AR-CB1R heterotetramer, Gi
and Gs bind to the external protomer of the CB1R and
A2AR homodimers, respectively, as we have previously
suggested for the A1R-A2AR and A2AR-D2R heterote-
tramers [6, 7]. The fact that the C-terminal α5-helix of
the G protein binds an intracellular cavity of the recep-
tor that is opened mainly by the outward movement of
TM 6 (TM 5 also moves but to a lesser extent), adds
complexity to the modeling process. Thus, the TM 4/6
interface was modeled with the internal protomer in the
inactive conformation (TM 6 closed) and the external
protomer in the active conformation (TM 6 open). The
stability of these interfaces was evaluated using MD sim-
ulations (see “Methods”), which yielded a converged
structure for the complex with steady values for both
root mean squared deviations and distance between pro-
tomers (not shown). Figure 3 shows a scheme (Fig. 3a)
and two different views of the computational model (Fig.
3b). The mechanism for receptor catalyzed nucleotide
exchange in G proteins involves a large-scale opening of
the α-helical domain (αAH) of the α-subunit, from the
Ras domain, allowing GDP to freely dissociate [42, 43].
Notably, the opening of αiAH and αsAH domains in the
proposed models of the A2AR-CB1R and A2AR-D2R
heteromers are pointing towards different directions
(Fig. 3a [7];), while they are facing each other in the
A1R-A2AR heteromer (Fig. 3b [6];).
The C-terminal domain of the partner receptor
determines the homomeric interfaces in the A2AR-CB1R
heterotetramer
A major question is the mechanism by which A2AR
changes the CB1R-CB1R homomeric interface and
CB1R changes the A2AR-A2AR interface (see above). A
remarkable difference between the quaternary structure
of the A2AR-CB1R heterotetramer and the A1R-A2AR
and A2AR-D2R heterotetramers is the proximity of the
C-terminal domain of the internal protomers to TM 5
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Fig. 3 Quaternary structure of the A2AR-CB1R heterotetramer. a Schematic representation of the A2AR-CB1R heterotetramer (left) viewed from
the extracellular side (colored arrows indicate the C-terminal segments of the internal protomers able to reach the external G protein-bound
protomers) and the previously reported A2AR-A1R (middle) and A2AR-D2R (right) heterotetramers. Inactive/internal and active/external protomers
of A2AR are shown in light and dark green, respectively, and inactive/internal and active/external protomers of CB1R, A1R, or D2R are shown in
orange and red, respectively. The α-subunit of the G protein is shown in light gray, the β-subunit in dark gray, and the γ-subunit in purple. The α-
helical domain (αAH) of the α-subunit, which performs a large-scale opening from the Ras domain, is shown in yellow. b A representative molecular
representation of the A2AR-CB1R heterotetramer obtained from the MD simulation viewed from the membrane (left) or from the extracellular side
(right). Color codes are as in panel a. c Proposed interaction between phosphorylated residues at the C-terminus of the CB1R (Gi-bound external
protomer) with arginine residues at the end of TM 5 of the A2AR (internal protomer). d Proposed interaction between phosphorylated residues at the
C-terminus of the A2AR (Gs-bound external protomer) with arginine residues at the end of TM 5 of the CB1R (internal protomer)
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and TM 6 of the external protomers (see arrows in Fig.
3a). Moreover, another difference among the three Gi-
coupled partners of the A2AR is the long C-terminal do-
main of CB1R (73 residues) as compared to that of the
A1R (34 residues) or the D2R (12 residues). We there-
fore speculated that the C-terminal domain of the part-
ner receptor could be responsible for the change in the
homomeric interface. To test this hypothesis, we engi-
neered an A2AR mutant lacking the C-terminal end
(A2AΔCTR) and evaluated BiFC of CB1R-nYFP and
CB1R-cYFP, in the presence and absence of each of the
peptides of CB1R, and in the presence of A2AΔCTR (Fig.
4a). While TM4 and TM6 reduced fluorescence in the
presence of A2AR (Fig. 2f, see above), TM4 and TM5,
but not TM6, reduced fluorescence in the presence of
A2AΔCTR (Fig. 4a). As an additional control, we tested
whether A2AΔCTR could modify the interface of the
A1R homodimer in the A1R-A2AR heterotetramer.
Clearly, the C-terminal domain of A2AR had no influence
in the A1R homodimer (Fig. 4b, c). The same as for Fig. 2,
the results in Fig. 4 are expressed as means ± S.E.M. of
the percentage of the fluorescence in the control group,
where control values (without interfering peptides) were
always between 12,000 and 15,000 RFU. Non-transformed
data show no significant change in fluorescence units
upon co-transfection with a non-fused receptor. Thus, we
can conclude that the C-terminal domain of A2AR modi-
fies the CB1R-CB1R homomeric interface stabilizing the
asymmetric TM 4/6 interface. Since the structure of the
heterotetramer is symmetrical, we hypothesize that the C-
terminal domain of CB1R also modifies the A2AR-A2AR
homomeric interface stabilizing the asymmetric TM 4/6
interface. These conclusions are in agreement with previ-
ous results in which we described strong electrostatic
interactions between phosphorylated Thr467-Ser468 at the
C-terminal domain of CB1R and Arg205(5.66)-
Arg206(5.67) at the intracellular end of TM 5 of A2AR as
well as between phosphorylated Ser374 at the C-terminal
domain of A2AR and the 215(5.64)VLRRRRKRVN224 epi-
tope at the intracellular end of TM 5 of D2R [11]. Here,
Fig. 4 A2AR C-terminus-guided homomeric interface of the CB1R homodimer in the A2AR-CB1R heterotetramer. a–c BiFC experiments with synthetic
peptides with the amino acid sequence of the TMs of CB1R and A1R. HEK-293T cells were transiently transfected with the following: a cDNA of two different
molecules of CB1R separately fused to complementary halves of YFP (CB1R-cYFP and CB1R-nYFP; 3 μg in both cases) with co-transfection with cDNA of non-
fused A2AR mutant lacking the C-terminal end (A2AΔCTR; 1 μg); b, c cDNAs of two different molecules of A1R separately fused to complementary halves of
YFP (A1R-cYFP and A1R-nYFP; 3 μg in both cases) with co-transfection with cDNA of non-fused A2AR (b; 1 μg) or non-fused A2AΔCTR (c; 1 μg). Cells were
treated for 4 h with medium (control) or 4 μM of indicated TM peptides (numbered 1–7). Values are means ± S.E.M. (n = 6 with
triplicates in all the experiments) of the percentage of the fluorescence in the control group and analyzed statistically with repeated
measures ANOVA, followed by Dunnett’s multiple comparison test (***: p < 0.001, compared with control)
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Fig. 5 (See legend on next page.)
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we propose similar interactions for the A2AR-CB1R
heterotetramer. Although it is not possible to model the
full-length C-terminal domain of either A2AR or CB1R,
we modeled phosphorylated Ser374 of A2AR and
phosphorylated Thr467-Ser468 of CB1R, connected by an
arbitrary C-terminal domain (dotted lines in Fig. 3c, d).
Figure 3c shows the electrostatic interactions between
phosphorylated Thr467-Ser468 of CB1R and Arg205(5.66)-
Arg206(5.67) of A2AR, and Fig. 3d shows the interaction
between phosphorylated Ser374 of A2AR and Lys300(5.66)-
Arg307(5.73)-Arg311(5.77) of CB1R. We hypothesize that
these electrostatic interactions are the driving force for the
conformational change, from the TM 4 interface of the
CB1R homodimer in the absence of A2AR and from the
TM 6 interface of the A2AR homodimer in the absence of
CB1R, to the TM 4/6 interface that orients TM 5 towards
the C-terminal domain of the partner receptor in the
A2AR-CB1R heterotetramer.
The A2AR-CB1R heterotetramer provides a frame for the
canonical Gs-Gi antagonistic interaction at the AC level
The ability of A2AR-CB1R heterotetramer to modulate
AC signaling was then tested in HEK-293T cells by
using heteromer-interfering peptides. As expected from
their respective coupling to Gi and Gs proteins, the
CB1R agonist CP55940 (200 nM) decreased cAMP for-
mation induced by forskolin (500 nM) and the selective
A2AR agonist CGS21680 (500 nM) increased cAMP in
cells transfected with CB1R or A2AR, respectively (Add-
itional file 1: Figure S4a and S4b). The same effect of
both ligands was observed in cells co-transfected with
A2AR and CB1R, where, in addition, CP55940 counter-
acted CGS21680-mediated increase in cAMP (Additional
file 1: Figure S4c). This is in agreement with the ability
of A2AR and CB1R to signal with their cognate G pro-
teins and to establish the canonical Gs-Gi antagonistic
interaction at the AC level in the A2AR-CB1R heterote-
tramer. Interfering peptides (TM4 to TM6 of CB1R and
A2AR) were then used to demonstrate the dependence
on the integrity of the A2AR-CB1R heterotetramer for
the existence of this canonical Gs-Gi antagonistic inter-
action, as previously shown for the A2AR-D2R heterote-
tramer [7]. None of these peptides significantly modified
the effect of either CP55940 or CGS21680 when activat-
ing their respective receptor (Fig. 5a–h; Additional file 2:
Data values 3). On the other hand, TM5 and TM6 of
both A2AR and CB1R, but not TM4 or TM7 (negative
control), counteracted the canonical interaction (Fig.
5a–h; Additional file 2: Data values 3). Since TM 4 and
TM 5 are selectively involved in homo- and heteromeri-
zation, respectively, while TM 6 is involved in both
homo- and heteromerization, these results demonstrate
that A2AR-CB1R heteromerization provides the neces-
sary frame for the canonical Gs-Gi antagonistic inter-
action at the AC level. This effect was also present in
the A2AR-D2R heterotetramer [7] but absent in the
A1R-A2AR heterotetramer, which was devoid of canon-
ical interaction [6]. This is rationalized by the fact that
simultaneous opening of αiAH and αsAH is feasible in
the A2AR-CB1R and A2AR-D2R heterotetramers (αAH
opening is towards different direction) and is not feasible
in A1R-A2AR because αiAH and αsAH face each other
(Fig. 3a) [6].
Experiments were also performed in cells trans-
fected with both receptors and pre-treated with per-
tussis toxin (PTX) or cholera toxin (CTX) (for details,
see legend to Additional file 1: Figure S4), which alter
Gi- and Gs-mediated signaling, respectively. As ex-
pected, we observed blockade of CP55940-induced
cAMP decrease by PTX, and blockade of CGS21680-
induced cAMP increase by CTX (Additional file 1:
Figure S4d and S4e). In addition, PTX and CTX also
blocked the effect of CGS21680 and CP55940, re-
spectively (Additional file 1: Figure S4d and S4e).
These results indicate that both A2AR- and CB1R-
mediated signaling in the A2AR-CB1R heterotetramer
are dependent on the functional integrity of both Gs
and Gi proteins. The same phenomenon has been
previously described for the A1R-A2AR heteromer [6,
44], while the toxins maintained their expected select-
ivity for either Gs or Gi in the A2AR-D2R heteromer
[7]. This cross-communication is not fully understood
but it could be related to the closer proximity of the
α-subunits of Gs and Gi coupled to the A2AR-CB1R
and A1R-A2AR heterotetramers.
Presynaptic A2AR-CB1R heterotetramers mediate the
cannabinoid-induced inhibition of striatal glutamate
release
The demonstration of the presence and functional sig-
nificance of A2AR-CB1R heteromers in striatal gluta-
matergic terminals was then approached by analyzing
(See figure on previous page.)
Fig. 5 Canonical Gs-Gi antagonistic interaction at the AC level in the A2AR-CB1R heterotetramer. a–h Effect of TM peptides on the cAMP formation
induced by forskolin (500 nM) or by the A2AR agonist CGS21680 (CGS, 500 nM) and counteractive effects of the CB1R agonist CP55940 (200 nM). HEK-
293T cells were transiently transfected with the cDNAs of CB1R and A2AR (2 μg in both cases) and treated for 4 h with 4 μM of peptides TM4, TM5,
TM6, or TM7 of the A2AR or CB1R. Values are means ± S.E.M. (n = 5 with triplicates in all experiments) of the percentage of forskolin-induced cAMP
formation and analyzed statistically with repeated measures ANOVA, followed by Dunnett’s multiple comparison test (*, **, and ***: p < 0.05, p < 0.01,
and p < 0.001, respectively, compared with basal; #, ##, and ###: p < 0.01 and p < 0.001, respectively, compared to forskolin or CGS)
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the ability of the CB1R agonist WIN55,212-2 to inhibit
depolarization-induced glutamate release from rat stri-
atal synaptosomes (see “Methods” and ref. [19]). We
would first expect that, as previously reported [19, 21],
A2AR agonists would reduce the effect, and more specif-
ically the potency, of WIN55,212-2. Second, we should
be able to demonstrate that A2AR antagonists would
produce the same effect as A2AR agonists and that when
co-applied they would counteract each other’s effect.
Third, if these effects of A2AR agonists and antagonists
would reflect functional correlations of the allosteric in-
teractions within the A2AR-CB1R heterotetramer, they
should be counteracted by a synthetic peptide that de-
stabilizes the heteromeric interface. Finally, we should
also find a correlate of the Gs-Gi canonical interaction
at the AC level. Indeed, as shown in Fig. 6a–d, WIN55,
212-2 inhibited evoked glutamate release (EC50, 5.5 nM)
in a concentration-dependent fashion, reaching its max-
imal effect (77.0 ± 3.0% of DMSO control) at 0.03 μM.
The concentration-response inhibitory curve of WIN55,
Fig. 6 A2AR-CB1R heteromer-mediated control of the evoked glutamate release from striatal nerve terminals. a Concentration-response curves of
the inhibitory effect of WIN55,2121-2 (WIN) on the evoked glutamate release, expressed as the difference in % of the control value, alone or in
the presence the A2AR agonist CGS21680 (CGS, 0.03 μM), the A2AR antagonist SCH58261 (SCH, 0.1 μM), or both. Data are means ± S.E.M. of 7–14
experiments with duplicates per treatment and concentration. b–d Individual results from the experiments shown in a with WIN at the concentrations
of 0.01 μM (b), 0.03 μM (c), and 0.1 μM (d), administered alone or in the presence of CGS (0.03 μM), SCH (0.1 μM), or both (yellow dots). e Effect of the
peptides TM5 and TM7 of the A2AR on the inhibitory effect of WIN (0.03 μM) on the evoked glutamate release, expressed as the difference in % of the
control value, alone or in the presence of CGS (0.03 μM) or SCH (0.1 μM). f Effect of CGS (0.03 μM), SCH (0.1 and 10 μM), or SCH (10 μM) plus WIN (0.3
μM). b–f Values are means ± S.E.M. (n = 7–14 with duplicates) of the evoked glutamate release, expressed as the difference in % of the control value,
and analyzed statistically with one-sample t-test (*: p < 0.05/3; see “Methods”)
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212-2 was shifted to the right both by the A2AR agonist
CGS21680 (EC50, 36.8 nM) and the A2AR antagonist
SCH58261 (EC50, 40.0 nM) alone, but not when co-
administered (EC50, 8.2 nM). In detail, CGS21680 (0.03
μM) and SCH58261 (0.1 μM) fully prevented the inhib-
ition by 0.01 and 0.03 μM, but not by 0.1 μM of WIN55,
212-2 of glutamate release (Fig. 6a–d). On the other
hand, co-application of both CGS21680 (0.03 μM) and
SCH58261 (0.1 μM) did not significantly modify the ef-
fect of WIN55,212-2 (Fig. 6a–d).
Striking results were obtained when evaluating the ef-
fect of the destabilizing A2AR-CB1R heteromer peptides.
TM5, but not TM7, of A2AR significantly blocked
WIN55,212-2-induced inhibition of glutamate release
and no additional change was observed with the applica-
tion of the A2AR ligands (Fig. 6e). These results would
indicate that WIN55,212-2-induced inhibition of glu-
tamate release is dependent on A2AR-CB1R heteromeri-
zation and would confirm the initial hypothesis of the
permissive role of A2AR for CB1R signaling in the
A2AR-CB1R heteromer [18]. But the results would also
indicate that the permissive role of A2AR would not rely
on a ligand-dependent A2AR activation.
Our assumption about presynaptic A2AR-CB1R het-
eromers determining all interactions between A2AR and
CB1R ligands at the level of striatal glutamatergic trans-
mission bears the question of how the activation of
A2AR can be needed for CB1R signaling while, at the
same time, A2AR ligands significantly decrease the po-
tency of CB1R ligands. A possible answer to this appar-
ent conundrum is the existence of a significant
constitutive activity of A2AR in the A2AR-CB1R hetero-
mer, which would produce a constitutive activation of
AC. A CB1R receptor ligand, including endocannabi-
noids, would inhibit A2AR-mediated constitutive AC
activation by the canonical Gi-Gs antagonistic inter-
action in the absence of A2AR ligands. In fact, a high
constitutive activity of A2AR has been previously re-
ported [45–47]. This would first imply that the CB1R-
mediated inhibition of glutamate release is dependent on
a Gi-coupling with or without heteromerization with
A2AR. Synaptosomes were incubated for 4 h at 4 °C
with or without PTX (2 μg/ml) before the regular release
experiment procedure. While WIN55,212-2 (0.1 μM)
significantly inhibited glutamate release in the toxin-
naïve synaptosomes (in mean ± S.E.M and expressed as
the difference in % of the control value: 82.9% ± 3.6%, n
= 6; one-sample t-test: p < 0.05/3; see “Methods”), PTX
fully prevented this inhibition (in mean ± S.E.M and
expressed as the difference in % of the control value:
114.6% ± 6.8, n = 6; one-sample t-test: p > 0.05/3). Fi-
nally, one would also expect that a high concentration of
the A2AR inverse agonist, SCH58261 [46], should lead
to a significant reduction of the ability of WIN55,212-2
to inhibit evoked glutamate release. Indeed, at 10 μM
(but not 0.1 μM), SCH58261 significantly inhibited the
evoked glutamate release, which could not be further
inhibited by a relatively high concentration of WIN55212-
2 (0.3 μM; Fig. 6f). These results therefore indicate that a
main mechanism by which CB1R localized in striatal
nerve terminals modulate glutamate release is by counter-
acting a constitutive A2AR-mediated facilitation of glu-
tamate release by a canonical Gi-Gs antagonistic
interaction dependent on A2AR-CB1R heteromerization.
The existence of a significant constitutive activity of
A2AR in the A2AR-CB1R heterotetramer was confirmed
with experiments in HEK-293T cells transiently trans-
fected with A2AR alone or with additional transfection
with CB1R, A1R, or D2R. A2AR showed a high constitu-
tive activity (about 250% increase in cAMP formation in
cells only transfected with A2AR, as compared with cells
transfected with an empty control vector; see “Methods”)
(Fig. 7; Additional file 2: Data values 4). Very dramatic
differential results were obtained when A2AR was co-
transfected with either CB1R, A1R, or D2R. Thus, A2AR
lost its constitutive activity when co-transfected with
A1R or D2R, but it was not significantly modified with
co-transfection with CB1R (Fig. 7; Additional file 2: Data
values 4). Therefore, these results indicate that the
Fig. 7 Differential A2AR constitutive activity (CA) in different A2AR
heteromers. Constitutive activation of AC in cells expressing A2AR
alone or with A2AR plus CB1R, A1R, or D2R. HEK-293T cells were
transiently transfected with the cDNA of A2AR alone (3 μg) or with
the cDNA of A2AR (1.5 μg) and the cDNA of CB1R, A1R, or D2R (1.5
μg in all cases). CA values are expressed as means ± S.E.M. (n = 5
with quintuplicates in all experiments) of the % of basal values,
calculated by dividing the levels of cAMP obtained in each
condition by the levels of cAMP in cells transfected with an empty
vector (pcDNA3, 3 μg). In addition, the values were normalized by
the levels of cell surface expression of A2AR, which was determined
by means of SNAP staining (see “Methods”). Statistical analysis was
performed by using one-way ANOVA, followed by Tukey’s multiple
comparison test (** and ***: p < 0.01 and p < 0.001, respectively,
compared with cells only transfected with A2AR)
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constitutive activity of A2AR is blunted by heteromeriza-
tion with either A1R or D2R, but not by heteromerization
with CB1R; activation of CB1R in the A2AR-CB1R hetero-
tetramer can, nevertheless, blunt the A2AR-mediated con-
stitutive activation of AC (see “Discussion”). The
molecular mechanism of this heteromerization-dependent
control of the constitutive activation of A2AR seems diffi-
cult to rationalize, but we hypothesize that the postulated
interaction between TM 5 of the Gs-bound A2AR proto-
mer and the C-terminal domain of the Gi-unbound CB1R
protomer (Fig. 3c), may help to sustain the constitutive ac-
tivity of A2AR in the A2AR-CB1R heterotetramer, in con-
trast to the short C-termini of the A1R or D2R in the
A1R-A2AR and A2AR-D2R heterotetramers (Fig. 3a). In
fact, TM 5 and TM 6 are the helices that move upon re-
ceptor activation.
Discussion
In the present study, using a peptide-interfering approach
combined with biophysical and biochemical techniques in
mammalian transfected cells and computational modeling,
we could establish the tetrameric quaternary structure of
the A2AR-CB1R heterotetramer, having the same hetero-
meric but different homomeric interfaces than those of
the A1R-A2AR heterotetramer. The long A2AR-CT
played a significant role, determining the homomeric
interface of the CB1R homodimer. The A2AR-CB1R het-
erotetramer showed the same allosteric interactions and
canonical Gs-Gi antagonistic interaction at the AC level as
the A2AR-D2R heterotetramer. The utilization of TAT-
fused TM peptides in mammalian transfected cells and
striatal primary neuronal cultures allowed demonstrating
that the canonical interaction at the AC level between
A2AR and D2R ligands required the right quaternary
structure of the A2AR-D2R heterotetramer in the A2AR-
D2R-AC5 complex. Application of TM peptides that spe-
cifically interfere with the heteromeric interface or with
the receptor-AC5 interface specifically counteracted the
ability of a D2R agonist to inhibit AC5 activation by an
A2AR agonist, but not with the ability of D2R ligands to
counteract forskolin-induced AC activation [7]. More gen-
erally, these results indicate that to inhibit a Gs-coupled
receptor-mediated AC activation, the ligands need to sim-
ultaneously interact with heterotetramers of the corre-
sponding Gs-coupled and Gi-coupled receptors. This has
been so far shown for the A2AR-D2R [7], the A1R-D1R
[48], the D1R-D3R [49], and now the A2AR-CB1R hetero-
tetramers, where destabilization of their heteromeric
interface leads to the disruption of the canonical Gs-Gi
antagonistic interaction at the AC level without disruption
of the Gi-coupled receptor-mediated inhibition of
forskolin-induced AC activation.
Different from the A2AR-D2R and A1R-A2AR hetero-
tetramers, the A2AR-CB1R heterotetramer showed a
significant A2AR-mediated constitutive activation of AC.
Using the peptide-interfering approach in rat striatal
synaptosomal preparations, we could then identify the
A2AR-CB1R heteromer in striatal glutamatergic termi-
nals, where it provides the main target by which canna-
binoids inhibit glutamate release. The present study
presents a new conceptual view about the mechanism by
which cannabinoids presynaptically control striatal exci-
tatory neurotransmission. Instead of the classically
assumed direct inhibition of glutamate release by CB1R-
mediated signaling, we demonstrate that cannabinoids
inhibit glutamate release indirectly, by counteracting the
stimulation of glutamate release induced by A2AR-
mediated signaling. This mechanism is completely
dependent on the heteromerization with A2AR, which
provides the frame for the canonical Gi-Gs antagonistic
interaction at the AC level. In addition, this mechanism
operates in the absence of an adenosine-mediated activa-
tion of the A2AR, by the ability of CB1R activation to
cancel A2AR-mediated constitutive activation of AC
within the A2AR-CB1R heteromer. We could also dem-
onstrate that the constitutive activity is also present
when the A2AR is not forming heteromers and that it is
lost upon heteromerization with A1R or D2R.
We recently provided the proof of concept of a ligand-
independent ability of one of the protomers in a GPCR
heteromer to modify the constitutive activity of the other
molecularly different protomer. That was the ability of the
dopamine D4 receptor (D4R) to modify the constitutive
activity in the D2R-D4R heteromer [32], also localized in
striatal glutamatergic terminals, where it mediates a pre-
synaptic dopaminergic inhibitory control of glutamate re-
lease [50–52]. This effect was even dependent on the
polymorphic variant of the D4R, demonstrating for the
first time a functional difference between the two most
common D4R polymorphic variants, D4.4 and D4.7 [52].
The D4.7R-mediated increase in the constitutive activity
of the D2R could explain the recently reported gain of
function of the D2R in the control of striatal glutamate
release when forming heteromers with the ADHD-
associated polymorphic variant D4.7R [52]. The constitu-
tive activity of the D2R in the D2R-D4R heteromers and
the constitutive activity of the A2AR in the A2AR-CB1R
seem therefore to determine the basal degree of sensitivity
of striatal glutamatergic terminals to release glutamate
upon depolarization.
The two A2AR heteromers, A2AR-CB1R and A1R-
A2AR, allow an adenosine-mediated fine-tuned modula-
tion of presynaptic striatal glutamatergic transmission,
which is moderated by the extracellular levels of endo-
cannabinoids [2] (Additional file 1: Figure S5). First, the
A2AR loses its constitutive activity when it forms het-
eromers with A1R and adenosine binds with more affin-
ity to A1R than to A2AR. As mentioned in the
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“Background”, low extracellular concentrations of ad-
enosine should predominantly activate A1R within the
A1R-A2AR heteromer, leading to a predominant inhib-
ition of glutamate release (Additional file 1: Figure S5a).
This would represent a mechanism of silencing corticos-
triatal “noise”. Retrograde endocannabinoid release fol-
lowing postsynaptic metabotropic glutamate receptor
activation [25] would further guarantee the low noise, by
counteracting the A2AR-mediated constitutive activation
of AC by the A2AR-CB1R heteromer (Additional file 1:
Figure S5a). Upon strong corticostriatal activity, the in-
crease in the presynaptic release and degradation of
ATP would create locally high levels of adenosine, which
in turn would activate A2AR to shut down A1R signal-
ing in the A1R-A2AR heteromer [3, 6] and to counteract
CB1R signaling in the A2AR-CB1R heteromer, switching
the effect of adenosine on glutamate release from inhib-
ition to facilitation (Additional file 1: Figure S5b). This
high-pass filter is expected to increase the reliability of
information passage and should be maximized under
conditions of low extracellular concentrations of endo-
cannabinoids [2].
The present study seems to be in contradiction with
our recent previous study, where A2AR-CB1R hetero-
mers were described to be preferentially coupled to Gq
and postsynaptically localized in the striatum, in
GABAergic striatopallidal neurons [53], while the
present study shows their presynaptic localization in glu-
tamatergic terminals and their preferential coupling to
Gs and Gi proteins. Although CB1R couples preferen-
tially to Gi/o proteins, its ability to couple to Gq has
already been reported and shown to be ligand-
dependent [53]. Thus, WIN55,212-2 was found to be
more and less potent than CP55940 at eliciting Gq-
dependent intracellular calcium increase and at inhibit-
ing forskolin-induced cAMP production, respectively
[53, 54]. Nevertheless, despite its relative functional se-
lectivity for Gq protein-mediated signaling, in the
present study, WIN55,212-2 was shown to inhibit stri-
atal glutamate release by a PTX-sensitive mechanism.
Therefore, the results of our previous and present stud-
ies indicate that the preference for a specific G protein
coupling of the A2AR-CB1R heteromer depends mostly
on the cellular environment. They also suggest that Gq
coupling depends on an additional component that is
present in immortalized striatal neuroblasts and
GABAergic striatopallidal neurons (previous study) and
absent in HEK-293T cells and glutamatergic terminals
(present study). One very plausible candidate is the
canonical Gq-coupled glutamate mGlu5 metabotropic
receptor, which is abundantly expressed postsynapyti-
cally in the striatum [25]. Thus, mGlu5R was previously
reported to form functional heteromers with A2AR [55,
56] and suggested to form complexes that include the
three different GPCRs [57]. Experiments are in progress
to determine if the striatal Gq protein coupling of post-
synaptic A2AR and CB1R depends on their ability to
separately or simultaneously form heteromers with
mGlu5R.
The important role of the A2AR-CB1R heteromer in
the inhibitory control of corticostriatal glutamate release
makes it a potential target for neuropsychiatric disorders
putatively associated with increased corticostriatal trans-
mission, which includes obsessive-compulsive disorder
[58], schizophrenia [59], and substance use disorders
[60]. In addition, changes in the stoichiometry of the
presynaptic A1R-A2AR and A2A-CB1R receptor hetero-
mers could have important implications in the patho-
genesis of neuropsychiatric disorders. For instance, in
Restless Legs Syndrome (RLS), there is recent preclinical
evidence for the existence of downregulation of striatal
A1R [61], which promotes an increased sensitivity of
corticostriatal terminals to release glutamate [51, 62].
This should be associated with a relative functional up-
regulation of presynaptic A2AR due to an increase in
the proportion of A2AR not forming heteromers or
forming heteromers with CB1R, both endowed with con-
stitutive activity. As expected, the increased sensitivity of
corticostriatal terminals observed in the experimental
animal could be counteracted by blocking the constitu-
tive signaling of A2AR, with A2AR inverse agonists or
CB1R agonists, or by activating A1R, by moderately in-
creasing extracellular levels of adenosine with an inhibi-
tor of the adenosine transporter. There is in fact
preliminary clinical evidence for the successful applica-
tion of these strategies in RLS patients [63–65].
Finally, more studies need to be done to evaluate the
possible existence of A2AR-CB1R heteromers, and
therefore, the same type of adenosine-cannabinoid-
mediated modulation of glutamate release, in other areas
of the CNS. It is very plausible that A2AR-CB1R hetero-
mers modulate neurotransmitter release in many other
brain areas, such as the hippocampus. Those heteromers
could mediate the reported ability of A2AR antagonists
to prevent cannabinoid-induced memory and LTP im-
pairments [66, 67].
Conclusions
We demonstrate that the ability of cannabinoids to con-
trol excitatory transmission in the striatum depends on
adenosine transmission, which is mediated by hetero-
mers of specific subtypes of adenosine and cannabinoid
receptors, A2AR and CB1R. The molecular analysis of
the A2AR-CB1R heteromers supports our hypothesis
about GPCR heteromers being often constituted by het-
eromers of homodimers [68]. It also supports that these
GPCR heterotetramers often include Gs- and Gi-
coupled homodimers, providing the frame for the
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canonical Gs-Gi antagonistic interaction at the adenylyl
cyclase level, forming part of GPCR signaling complexes
that include GPCR heteromers and their common inter-
acting effectors [7, 69]. The comparison of the A2AR-
CB1 receptor with other heterotetramers of A2AR added
new information about the properties of GPCRs. It re-
vealed that different heteromeric partners of A2AR de-
termine profound differences in their pharmacological
properties. This implies the need to consider the imme-
diate context of a GPCR to truly understand its pharma-
cological properties and, therefore, its role in drug
development.
Methods
Expression vectors and fusion proteins
Sequences encoding amino acids (aa) residues 1-229 and
230-311 of Rluc (Rluc8 variant) and amino acid residues
1-155 and 156-238 of YFP (mVenus variant) were sub-
cloned in pcDNA3.1 vector to obtain complementary
Rluc and YFP hemi-truncated proteins (nRluc, cRluc,
nYFP, and cYFP). The cDNAs for human CB1R, A2AR,
A1R, D1R, D2R (short isoform), and 5-HT2AR cloned
into pcDNA3.1 were amplified without their stop codons
using sense and antisense primers harboring EcoRI and
BamHI sites to clone A2AR and D1R or EcoRI and KpnI
to clone A1R and CB1R. The amplified fragments were
subcloned to be in-frame with restriction sites of
pcDNA3.1-nYFP, pcDNA3.1-cYFP, pcDNA3.1-nRluc, or
pcDNA3.1-Rluc vectors to provide plasmids that express
the receptor fused to nYFP, cYFP, nRluc, or cRluc on
the C-terminal end of the receptor. The following hu-
man G protein constructs were used: Gαi1-YFP (with
YFP, mVenus variant, inserted at position 91), Gαs-YFP
(with YFP, mVenus variant, inserted at position 154 of
Gαs, short isoform), and Gαq-YFP (with YFP, mVenus
variant, inserted at position 97 of Gαs), untagged Gβ1,
and untagged Gγ2. All the constructs were confirmed by
sequencing analysis. Several constructs were shared by
C. Gales at INSERM (Toulouse, France; Gαi1 construct)
and N. Lambert (Georgia Regents University, Augusta,
GA; Gαs). The expression of constructs was tested by
confocal microscopy and the receptor-fusion protein
functionality by ERK1/2 phosphorylation. An A2AR mu-
tant with a deletion of aa 321 to aa 412 on the C-
terminal domain of A2AR (A2AΔCTR) was generated as
previously described [70].
HIV TAT-fused TM peptides
Peptides with the amino acid sequence of TMs of the
CB1R, A2AR, and A1R were used as oligomer-
destabilizing agents, as previously demonstrated [6, 7,
12, 31, 71]. To allow intracellular delivery, a peptide can
be fused to the cell-penetrating HIV transactivator of
transcription (TAT) peptide (YGRKKRRQRRR). HIV
TAT fused to a TM GPCR peptide can be inserted ef-
fectively into the plasma membrane as a result of both
the penetration capacity of the TAT peptide and the
hydrophobic property of the TM peptide [72]. To obtain
the right orientation of the membrane-inserted peptide,
HIV TAT peptide was fused to the C-terminus of
peptides with the amino acid sequence of TM 1, TM 3,
TM 5, and TM 7 of CB1R, A2AR, or A1R (TM1, TM3,
TM5, and TM7 peptides, respectively) or to the N-
terminus of TM 2, TM 4, and TM 6 of CB1R, A2AR, or
A1R (TM2, TM4, and TM6 peptides, respectively). All
peptides were synthesized by Genemed Synthesis, Inc.
Their sequences were as follows:
VYITVELAIAVLAILGNVLVCWAVWYGRKKRRQRRR


































Cell cultures and transient transfection
Human embryonic kidney 293T (HEK-293T) cells ob-
tained from ATCC were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Gaithersburg, MD)
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supplemented with 2 mM L-glutamine, 100 μg/ml so-
dium pyruvate, 100 U/ml penicillin/streptomycin, MEM
non-essential amino acid solution (1/100), and 5% (v/v)
heat inactivated fetal bovine serum (FBS) (all supple-
ments were from Invitrogen, Paisley, Scotland, UK).
Cells were maintained at 37 °C in an atmosphere of 5%
CO2. For transient transfection, HEK-293T cells growing
in six-well dishes were transfected with the correspond-
ing fusion protein cDNA by the PEI (PolyEthylenImine,
Sigma-Aldrich, Saint Louis, MO) method. Cells were in-
cubated (4 h) with the corresponding cDNA together
with PEI (5.47 mM in nitrogen residues) and 150 mM
NaCl in a serum-starved medium. After 4 h, the medium
was changed to a fresh complete culture medium. Forty-
eight hours after transfection, cells were washed twice in
quick succession in Hank’s balanced salt solution (HBSS;
containing, in mM: 137 NaCl, 5 KCl, 0.34 Na2HPO4,
0.44 KH2PO4, 1.26 CaCl2, 0.4 MgSO4, 0.5 MgCl2, 10
HEPES, pH 7.4), supplemented with 0.1% glucose (w/v),
detached, and resuspended in the same buffer. To con-
trol the cell number, sample protein concentration was
determined using a Bradford assay kit (Bio-Rad, Munich,
Germany) using bovine serum albumin dilutions as
standards.
Bimolecular fluorescence complementation (BiFC)
HEK-293T cells transfected with the receptor fused to n-
YFP and the receptor fused to the cYFP were treated with
vehicle or the indicated TAT-fused TM peptides (4 μM)
for 4 h at 37 °C. To quantify protein-reconstituted YFP
Venus expression, cells (20 μg protein) were distributed in
96-well microplates (black plates with a transparent bot-
tom; Porvair, King’s Lynn, UK), and emission fluorescence
at 530 nm was read in a Fluo Star Optima Fluorimeter
(BMG Labtechnologies, Offenburg, Germany) equipped
with a high-energy xenon flash lamp, using a 10-nm-
bandwidth excitation filter at 400 nm reading. Protein
fluorescence was determined as fluorescence of the sam-
ple minus fluorescence of non-transfected cells. Cells ex-
pressing CB1R, A2AR, A1R, or D1R fused to nYFP or to
cYFP, as well as cells expressing nYFP or cYFP or both
complementary proteins (not fused to receptors) showed
similar fluorescence levels to non-transfected cells.
Bioluminescence resonance energy transfer (BRET) with
donor and acceptor complementation
HEK-293T cells were transfected with the corresponding
receptors fused to nYFP, cYFP, nRluc, and cRluc (see
figure legends). To quantify receptor-YFP expression,
cells (20 μg protein) were distributed in 96-well micro-
plates (black plates with a transparent bottom) and
fluorescence at 530 nm was read as described above. Re-
ceptor fluorescence was determined as fluorescence of
the sample minus the fluorescence of cells expressing
only the BRET donor. For BRET measurements, cells (20
μg protein) were distributed in 96-well microplates (Corn-
ing 3600, White plates; Sigma-Aldrich) and BRET signal
was collected 1 min after addition of 5 μM coelenterazine
H (Molecular Probes, Eugene, OR) using a Mithras LB
940 microplate reader (Berthold Technologies, Bad Wild-
bad, Germany), which allows integration of the signals de-
tected in the short-wavelength filter at 485 nm (440–500
nm) and the long-wavelength filter at 530 nm (510–590
nm). To quantify receptor-Rluc reconstitution, lumines-
cence readings were also performed after 10 min of adding
5 μM of coelenterazine H. Both the fluorescence and lu-
minescence of each sample were measured before each
experiment to confirm similar donor expression (∼150,000
luminescent units). Net BRET is defined as [(long-wave-
length emission)/(short-wavelength emission)]-Cf where
Cf corresponds to [(long-wavelength emission)/(short-
wavelength emission)] for the Rluc construct expressed
alone in the same experiment. BRET is expressed as milli
BRET units (mBU; net BRET × 1000).
Complemented donor-acceptor resonance energy transfer
(CODA-RET)
HEK-293T cells transfected with A2AR fused to cRluc
and CB1R fused to nRluc, or 5-HT2AR fused to cRluc
and D2R (short isoform) fused to nRluc, and co-
transfected with either Gαs, Gαi1, or Gαq fused to YFP
were harvested, washed, and resuspended in phosphate-
buffered saline (PBS). About 200,000 cells/well were dis-
tributed in 96-well plates, and 5 μM coelenterazine H
was added to each well. One minute after addition of
coelenterazine, different concentrations of the non-
selective adenosine receptor agonist NECA, the selective
CB1R agonist CP55940, dopamine, or serotonin were
added to each well. In some experiments, NECA or caf-
feine were added 12 min before the addition of
CP55940. Fluorescence of the acceptor was quantified
(excitation at 500 nm and emission at 540 nm for 1-s re-
cording) in the Mithras LB940 reader to confirm the
constant expression level across experiments. In parallel,
BRET signal from the same batch of cells was deter-
mined as the ratio of the light emitted by YFP (mVenus
variant; 510–540 nm) over Rluc (485 nm). Results were
calculated for the BRET change (BRET ratio for the cor-
responding drug minus BRET ratio in the absence of the
drug) 10 min after addition of the agonists. Data manip-
ulations and statistical analyses for all CODA-RET,
BRET, and complementation experiments were per-
formed with GraphPad Prism 7.0 software (La Jolla, CA).
cAMP accumulation
cAMP accumulation was measured using the LANCE
Ultra cAMP kit (PerkinElmer, Waltham, MA, USA) as
previously described [73]. In brief, HEK-293T cells were
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seeded in white 384-wells plates in Dulbecco’s modified
Eagle’s medium (DMEM) (Sigma-Aldrich) containing
zardaverine (up to 50 μM; Calbiochem, San Diego, CA,
USA) and, when using A2AR ligands, adenosine deami-
nase (ADA, 0.5 U/ml; Roche Diagnostics, GmbH, Mann-
heim, Germany). Cells were incubated for 1 h at 37 °C
and for 4 h at 37 °C when using TAT-fused TM pep-
tides. Subsequently, selective ligands and/or forskolin
were added and cells were incubated for 30 min. Finally,
Eu-cAMP tracer and ULight™-anti-cAMP reagents were
prepared and added to the sample following the manu-
facturer’s instructions. The 384-wells plate was incu-
bated 1 h at 22 °C in the dark and was then read on a
CLARIOstar or PHERAstar microplate reader (BMG
Labtech, Durham, NC, USA). Measurements at 620 nm
and 665 nm were used to detect the TR-FRET signal
and the concomitant cAMP levels were calculated fol-
lowing the manufacturer’s instructions. Data were fitted
by non-linear regression using GraphPad Prism 6.01
(San Diego, CA, USA). When comparing the effect of
different co-expression experiments, cells were labeled
by means of SNAP staining as previously described [47]
and cAMP values were normalized according to the
levels of cell surface expression of A2AR in each condi-
tion (A2AR, A2AR + A1R, A2AR + CB1R, A2AR +
D2R). In brief, adherent cells expressing the A2AR
SNAP
were washed and incubated with DMEM containing 100
nM of SNAP-surface 488 substrate (New England Bio-
Labs, Ipswich, MA) for 1 h at 37 °C. Cells were then
washed three times with phenol red-free Hank’s bal-
anced salt solution containing 1 g/l glucose (HBSS: 137
mM NaCl, 5.4 mM KCl, 0.3 mM Na2HPO4, 0.4 mM
KH2PO4, 4.2 mM NaHCO3, 1.3 mM CaCl2, 0.5 mM
MgCl2, 0.6 mM MgSO4, 5.6 mM glucose, pH 7.4) and
fluorescence read on the CLARIOstar microplate reader
(BMG Labtech).
Computational model of the A2AR-CB1R heterotetramer
The structural model of the A2AR-CB1R heterotetramer
consists of a heteromer of homodimers. The A2AR ho-
modimer is formed by an internal inactive protomer
(interacting with CB1R), modeled with PDB id 5NM4
[74, 75], and an external active protomer bound to Gs,
modeled with PDB id 5G53 of A2AR in complex with a
mini-Gs α-subunit [76, 77]. Gs was modeled based on
the mini-Gs α-subunit and the βγ-subunits of the
A2AR-Gs structure with PDB id 6GDG [78, 79]. The
CB1R dimer is formed by an internal inactive protomer
(interacting with A2AR), modeled with PDB id 5U09
[80, 81], and an external active protomer bound to Gi,
modeled with PDB id 6N4B of the CB1R-Gi complex
[82, 83]. The A2AR-CB1R heteromer was modeled via
the TM 5/6 interface, using the structure of the μ-opioid
receptor with PDB id 4DKL [39, 84]. TMs 5 and 6 of
inactive A2AR and CB1R were modeled as observed on
the structure of the μ-opioid receptor to facilitate the
formation of the highly packed TM 5/6 interface. The
A2AR and CB1R homodimers were modeled via the TM
4/6 interface, using the structure of CB2R with PDB id
5ZTY [85, 86]. The large outward movement of TM 6
for G protein coupling is not compatible with the TM 4/
6 interface observed in this structure due to steric
clashes. To avoid these clashes, the active protomer was
manually rotated relative to the inactive protomer. The
resulting tetrameric complex was refined using a 800-ns
molecular dynamics simulation (as described in detail
elsewhere [6]).
[14C]glutamate release assay from striatal glutamatergic
terminals
Male Wistar rats (180–240 g, 8-10 weeks old) were pur-
chased from Charles-River (Barcelona, Spain), and
housed with 12-h light on/off cycles under controlled
temperature (23 ± 2 °C) and ad libitum access to food
and water. Before brain extraction, the rats were deeply
anesthetized with halothane (5%, 1 l/min flow rate; no
reaction to tail pinch or handling, while still breathing).
Experiments were carried out as previously described
[19]. Briefly, the two striata were rapidly dissected in ice-
cold Krebs’ solution (in mM: NaCl 132, KCl 3, KH2PO4
1.2, MgSO4 1.2, CaCl2 2.5, NaHCO3 25, glucose 5.5,
HEPES 10; pH 7.4) and moved into 2 ml of ice-cold su-
crose solution (0.32 M, containing 15 mM HEPES; pH
7.4) for homogenization with a Teflon homogenizer
(Thomas Scientific, NJ, USA). The heavy debris particles
in the homogenate were decanted at 1000g for 10 min at
4 °C, and the supernatant was saved. The first pellet (P1)
was resuspended once again and centrifuged as above.
Subsequently, the supernatants from the two centrifuga-
tions were pelleted at 20,000g for 30 min, to obtain the
P2 crude synaptosomal fraction. The two P2 pellets (syn-
aptosomes) from each rat were subsequently combined
and stored on ice until use. For the assays with pertussis
toxin (PTX), synaptosomes from each animal were re-
suspended in 2 ml of Krebs-HEPES solution, pregassed
with 95% O2 and 5% CO2, containing PTX (2 μg/ml)
and left tightly sealed at 4 °C for 4 h, then pelleted again
for [3H]glutamate loading. Hereafter, all assay solutions
contained the glutamate decarboxylase inhibitor, ami-
nooxyacetic acid (100 μM), to prevent the transfer of
[3H] labels to releasable molecules other than glutamate.
Before the release experiments, synaptosomes from each
animals were resuspended in 0.5 ml pregassed Krebs-
HEPES solution and incubated in the presence of
[3H]glutamate (specific activity, 60 Ci/mmol; final con-
centration, 200 nM; American Radiolabeled Chemicals
Inc, Saint Louis, MO) for 15 min. When necessary, incu-
bations with TM5 (20 μM) or with TM7 (20 μM) of
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A2AR occurred also during this period. Subsequently, a
8-microvolume chamber superfusion setup was filled
with preloaded synaptosomes (chambers/rat) which were
trapped by layers of Whatman GF/B filters (Sigma-Al-
drich). Synaptosomes were superfused continuously at a
rate of 0.8 ml/min with pre-gassed Krebs-HEPES solu-
tion (37 °C) until the end of the experiments. Upon ter-
mination of a 10-min washout and after collecting three
2-min samples as baseline, neurotransmitter release was
stimulated twice with 30 mM KCl (S1, S2) with 10-min
interval (Fig. 6a). The CB1R agonist WIN55,212-2
(Tocris Bioscience, Bristol, UK), A2AR ligands (Tocris
Bioscience), or their solvent, DMSO (0.1% v/v), were
added to the superfusion medium 4 min before S2 and
continued to be present until the end of the experiment
(that is, there was no washout study).
Treatments were performed in duplicate (i.e., 1 pair of
control versus 3 pairs of different treatments per animal),
and the intra-chamber S2/S1 ratios served to evaluate the
effect of drug treatments and expressed as % of DMSO
control (Fig. 6a). All data are represented as means ±
S.E.M. of “n ≥ 5” observations (rats) in duplicates. As
control S2/S1 ratios do not have biological significance,
they were taken as 100% in each experiment, and treat-
ment S2/S1 ratios were normalized to them. Normalized
data were then tested for normal distribution by the
Kolmogorov-Smirnov test, and subsequently analyzed
with one-sample t-test against the hypothetical value of
100 (%), and p < 0.05/3 (a correction factor for three
treatments using one control) was accepted for signifi-
cant difference. Tests were performed using the Graph-
Pad Prism 5.0 software.
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